An indirect response model of homocysteine suppression by betaine: optimising the dosage regimen of betaine in homocystinuria

Br J Clin Pharmacol. 2002 Aug;54(2):140-6. doi: 10.1046/j.1365-2125.2002.01620.x.

Abstract

Aims: To investigate the pharmacokinetics (PK) and pharmacodynamics (PD) of betaine in the treatment of classical homocystinuria due to cystathionine beta-synthase (CbetaS) deficiency with a view to optimizing the dosage regimen.

Methods: Betaine was given as a single oral dose of 100 mg kg(-1) to six patients (age range 6-17 years) who normally received betaine but whose treatment had been suspended for 1 week prior to the study. Plasma betaine and total homocysteine concentrations were measured by high performance liquid chromatography (h.p.l.c.) at frequent intervals over 24 h. The best-fit PK model was determined using the PK-PD program Win-Nonlin and the concentration-time-effect data analysed by an indirect PD model. Using the PK and PD parameters, simulations were carried out with the aim of optimizing betaine dosage.

Results: Betaine PK was described by both mono- and bi-exponential disposition functions with first order absorption and a lag time. The correlation coefficient between betaine oral clearance and body weight was 0.6. Mean betaine clearance was higher in males than in females (P=0.03). PK-PD simulation indicated minimal benefit from exceeding a twice-daily dosing schedule and a 150 mg kg(-1) day(-1) dosage for betaine.

Conclusions: PK-PD modelling allows recommendations for optimal dosage of betaine in the treatment of homocystinuria, that have the potential for improved patient compliance and both therapeutic and pharmacoeconomic benefit.

MeSH terms

  • Administration, Oral
  • Adolescent
  • Betaine / administration & dosage
  • Betaine / pharmacokinetics*
  • Betaine / pharmacology
  • Child
  • Cystathionine beta-Synthase / deficiency
  • Dose-Response Relationship, Drug
  • Female
  • Homocysteine / antagonists & inhibitors
  • Homocysteine / blood
  • Homocystinuria / drug therapy*
  • Homocystinuria / etiology
  • Homocystinuria / metabolism
  • Humans
  • Male
  • Pyridoxine / therapeutic use
  • Treatment Failure

Substances

  • Homocysteine
  • Betaine
  • Cystathionine beta-Synthase
  • Pyridoxine